Eupraxia Pharmaceuticals Inc. (EPRX)

Eupraxia Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Selling, General & Admin	18.61	17.1	10.92	7.48	3.99	6.48
Research & Development	28.66	21.33	16.08	20.36	13.63	7.58
Operating Expenses	47.27	38.43	27	27.85	17.62	14.15
Operating Income	-47.27	-38.43	-27	-27.85	-17.62	-14.15
Interest Expense	-	-	-0.96	-1.17	-0.98	-0.97
Interest & Investment Income	2.18	1.41	1.16	0.86	0.43	0.05
Currency Exchange Gain (Loss)	0.63	-1.56	-0.16	0.07	0.24	0.16
Other Non Operating Income (Expenses)	-	-	1.2	-0.84	-1.06	-4.74
EBT Excluding Unusual Items	-44.46	-38.58	-25.76	-28.92	-18.98	-19.65
Gain (Loss) on Sale of Assets	-0	-0	0.02	-0	-0.01	-
Other Unusual Items	-	-	-	-	-	0.42
Pretax Income	-44.46	-38.59	-25.74	-28.93	-18.99	-19.23
Income Tax Expense	0.03	0.02	0	0.04	-	-
Earnings From Continuing Operations	-44.49	-38.61	-25.74	-28.97	-18.99	-19.23
Minority Interest in Earnings	0.03	0.03	0.24	0.75	0.5	0.3
Net Income	-44.47	-38.58	-25.5	-28.22	-18.49	-18.93
Preferred Dividends & Other Adjustments	2.53	2.53	0.43	-	-	-
Net Income to Common	-47	-41.11	-25.93	-28.22	-18.49	-18.93
Shares Outstanding (Basic)	45	40	34	24	19	12
Shares Outstanding (Diluted)	45	40	34	24	19	12
Shares Change (YoY)	26.83%	17.76%	40.52%	25.21%	55.45%	102.75%
EPS (Basic)	-1.04	-1.03	-0.76	-1.17	-0.96	-1.53
EPS (Diluted)	-1.04	-1.03	-0.76	-1.17	-0.96	-1.53
Free Cash Flow	-33.44	-29.14	-30.1	-20.82	-14.63	-12.06
Free Cash Flow Per Share	-0.74	-0.73	-0.89	-0.86	-0.76	-0.97
EBITDA	-47.06	-38.27	-26.89	-27.73	-17.51	-14.11
D&A For EBITDA	0.21	0.16	0.11	0.11	0.11	0.04
EBIT	-47.27	-38.43	-27	-27.85	-17.62	-14.15

Updated Mar 31, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q